Q1 2018 EPS Estimates for Bristol-Myers Squibb Co Lifted by Analyst (BMY)

Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at William Blair upped their Q1 2018 EPS estimates for Bristol-Myers Squibb in a research note issued to investors on Tuesday. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.84 for the quarter, up from their previous estimate of $0.73. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2018 earnings at $0.81 EPS, Q3 2018 earnings at $0.81 EPS and FY2018 earnings at $3.23 EPS.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share.

A number of other research analysts have also commented on BMY. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a report on Thursday. Leerink Swann raised their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a report on Tuesday. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a report on Tuesday. Piper Jaffray Companies reissued a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $65.58.

Bristol-Myers Squibb (NYSE:BMY) opened at $62.69 on Thursday. The company has a market capitalization of $102,506.52, a price-to-earnings ratio of 106.25, a PEG ratio of 1.95 and a beta of 1.09. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a fifty-two week low of $51.46 and a fifty-two week high of $66.10.

A number of hedge funds have recently made changes to their positions in BMY. Essex Investment Management Co. LLC boosted its position in shares of Bristol-Myers Squibb by 20.5% in the 2nd quarter. Essex Investment Management Co. LLC now owns 23,676 shares of the biopharmaceutical company’s stock valued at $1,319,000 after purchasing an additional 4,029 shares during the period. Papp L Roy & Associates boosted its position in shares of Bristol-Myers Squibb by 23.2% in the 2nd quarter. Papp L Roy & Associates now owns 6,900 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 1,300 shares during the period. Sei Investments Co. boosted its position in shares of Bristol-Myers Squibb by 1.4% in the 2nd quarter. Sei Investments Co. now owns 665,573 shares of the biopharmaceutical company’s stock valued at $37,085,000 after purchasing an additional 8,890 shares during the period. Oakworth Capital Inc. boosted its position in shares of Bristol-Myers Squibb by 2.0% in the 2nd quarter. Oakworth Capital Inc. now owns 11,049 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 219 shares during the period. Finally, YHB Investment Advisors Inc. boosted its position in shares of Bristol-Myers Squibb by 7.3% in the 2nd quarter. YHB Investment Advisors Inc. now owns 61,989 shares of the biopharmaceutical company’s stock valued at $3,454,000 after purchasing an additional 4,197 shares during the period. 69.70% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.55%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2018/02/09/q1-2018-eps-estimates-for-bristol-myers-squibb-co-lifted-by-analyst-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply